The Food and Drug Administration says patients should not stop taking Vytorin or other cholesterol-lowering drugs, based on its review of a controversial study. The agency is sticking to its original position that medicines that reduce bad cholesterol benefit patients at risk of heart attack or stroke. The FDA says it has finished reviewing the study, which compared Vytorin to one of the combination pill’s components, Zocor, that’s available as a much cheaper generic drug.
Last January, the study results showed Vytorin was no better than Zocor at reducing plaque buildup in arteries. That led some doctors to urge patients to abandon Vytorin. Now the FDA says patients shouldn’t do that, because Vytorin reduced bad cholesterol more than Zocor. You may recall that it was reported in May of last year that Vytorin could cause cancer. Apparently, that is no longer of concern to the FDA.
Source: Associated Press
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.